CTOs on the Move

Healthplus of Michigan

www.healthplus.com

 
Healthplus of Michigan is a Flint, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Hometown Health

Hometown Health is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mosaic Dental Collective

We Put Our Patients First We’re a dental collective that’s lead by doctors and on a mission to put people at the center of dentistry. Get in Touch Partnerships Get the Support You Deserve Join a collective of dentists who work together to create a dent...

Children's Medical Center

Children's Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Dayton, OH. To find more information about Children's Medical Center, please visit www.childrensdayton.org

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.